Is it relevant to use an interleukin-1-inhibiting strategy for the treatment of patients with deficiency of interleukin-36 receptor antagonist?

Authors


  • Funding sources: none.
  • Conflicts of interest: H.B. has been involved with Abbvie, Amgen, Boehringer, Celgene, Janssen, Eli-Lilly, Novartis and Pfizer; M.V. with Abbvie, Novartis and Pfizer; and A.S. with Pfizer.

No abstract is available for this article.

Ancillary